Navigation Links
Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
Date:10/25/2007

All Doses of VYVANSE Studied Demonstrated Significant Efficacy Within One

Week of Daily Treatment

BOSTON, Oct. 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once- daily VYVANSE(TM) (lisdexamfetamine dimesylate), the first prodrug stimulant. Findings from this phase III pivotal trial were presented today at a national psychiatric meeting in Boston, Mass.

"Adults with ADHD may experience significant impairments in their ability to focus, and organize and complete tasks, which could affect their work, family life and personal relationships," said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD Program at New York University School of Medicine and author of Scattered Minds: Help and Hope for Adults with ADHD. "The results of this study demonstrated that VYVANSE significantly improved the core symptoms of ADHD in adult study patients."

Results of Phase III Pivotal Trial

In this double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years, treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo and improvements were observed in the first week of the study.

All doses of VYVANSE showed significant improvements in the average change in ADHD Rating Scale (ADHD-RS-IV) scores, as measured from the study's start to end, the primary endpoint of this study. ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing their response to treatment. The scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the Diagnostic and Statisti
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets has announced ... X-ray Film Industry Report 2014" report to their ... Global And Chinese Medical X-Ray Film Industry Report ... current state of the Global medical X-ray film industry ... report provides a basic overview of the industry including ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Needles Market 2014-2018" report to their offering. ... hypodermic needle is a hollow needle commonly used with ... or to extract fluids from it. A hypodermic needle ... inject substances that cannot be ingested. Hypodermic needles are ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3
... Oct. 13, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in ... of a Multicenter Phase l/2 Trial" reporting Phase ... the treatment of advanced multiple myeloma (MM) patients, was ...
... PALO ALTO, Calif., Oct. 13, 2011 Telik, Inc. ... of a Phase 2b clinical trial to evaluate Telintra ... transfusion dependent, non-deletion (5q) myelodysplastic syndrome (MDS), who have ... Vidaza® or Dacogen®.  This patient population represents the majority ...
Cached Medicine Technology:Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 2Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 3Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 4Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome 2Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome 3
(Date:7/12/2014)... rise in the number of mobility devices around the ... suit the upsurge. Virtualization has become a growing trend ... The data traffic has increased by several folds with ... in larger and more complex networks. These global factors ... , The North American (NA) region is expected to ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP notes ... metal ion levels to the failure of metal-on-metal hip ... issue of The Journal of Bone & Joint Surgery, ... unilateral Articular Surface Replacement prostheses at least twelve months ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4
... early childhood exposures to industrial chemicals in the environment ... neurodevelopmental disorders (NDDs)—autism,// attention deficit disorder (ADHD), and mental ... identify the individual chemicals that can cause injury to ... new review study, published in the print issue of ...
... treating common ear infections in children with ear tubes ... antibiotic ear drops over antibiotics swallowed// in pill or ... Center researcher reports. ,The latest study, involving ... and faster in treating middle ear infections in children ...
... publication in the Journal of Clinical Endocrinology and ... provided by The Hormone Foundation, the public education ... Lifestyle Accelerates Testosterone Decline ... but a new study confirms that many health ...
... certain vitamins, in order to reach out to the needful ... to be made a compulsion in bread would prevent neural ... prove to be harmful towards older people as folic acid ... and nervous problems in the long run. ,The pain ...
... as one of the toughest and most strenuous jobs. A ... the workload// and strain makes them sick. ,The ... nearly 19,000 nurses, which included registered nurses, licensed practical nurses ... that nurses face a variety of physical and emotional challenges ...
... will soon be reaching out to hundreds of people ... and support//. ,The US-based AIDS Healthcare Foundation (AHF) ... in Assam's main city of Guwahati, the eastern town ... ,India's National AIDS Control Organisation (NACO) and ...
Cached Medicine News:Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 3Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 4Health News:Antibiotic Ear Drops Favored Over Oral Antibiotics for Ear Infections 2Health News:Testosterone Decline in Men Linked to Lifestyle, Increases in Obese Girls 2Health News:Folic Acid Supplementation in Bread: Boon to Neonates and Curse to Pensioners 2Health News:US NGO to Counsel HIV/AIDS Patients in Assam 2
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Medicine Products: